# Progentos Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/progentos-therapeutics

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.progentos.com
- Total disclosed funding: $69M
- Latest round: Series A (May 3, 2024)
- Investors on record: 5

## About

Founded in 2024 by co-founders Chris Loose and Sanjay Magavi and based in Massachusetts, US, Progentos Therapeutics offers research and manufactures medicines for chronic illnesses like multiple sclerosis. In May 2024, Progentos Therapeutics raised USD 65 million in Series A funding led by investor Forbion, with participation from other investors Alta Partners, Mission BioCapital, Longwood Fund, and Dolby Family Ventures.
 
Progentos is developing small-molecule drugs that target oligodendrocyte progenitor cells, which are responsible for producing myelin and activating cells to promote myelin regeneration, potentially restoring function lost due to MS damage.

The company will use the May 2024 funding to grow and broaden its MS program and pipeline of the organization.

## Funding rounds

- Series A, May 3, 2024, $69M — Alta Partners, Forbion, Longwood Fund, Dolby Family Ventures, Mission Biocapital

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series A
- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Series A
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Series A